{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:32:47Z","timestamp":1790731967712,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1037,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1124\/jpet.121.000743","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T01:00:26Z","timestamp":1642208426000},"page":"210-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease"],"prefix":"10.1016","volume":"380","author":[{"given":"Patricia","family":"Schroeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertik","family":"Fulzele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Ribadeneira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Wilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Gary","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Fessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamantis G.","family":"Konstantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie G.","family":"Seu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-9686","authenticated-orcid":false,"given":"Theodosia A.","family":"Kalfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000743_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: drug review","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1124\/jpet.121.000743_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000743_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2003.04781.x","article-title":"Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells","volume":"124","author":"Banerjee","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1124\/jpet.121.000743_bib4","doi-asserted-by":"crossref","first-page":"15320","DOI":"10.1073\/pnas.0904614106","article-title":"ATP-dependent mechanics of red blood cells","volume":"106","author":"Betz","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000743_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.25325","article-title":"Addressing the diagnostic gaps in pyruvate kinase deficiency: consensus recommendations on the diagnosis of pyruvate kinase deficiency","volume":"94","author":"Bianchi","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1124\/jpet.121.000743_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-019-01254-2","article-title":"Crizanlizumab: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/jpet.121.000743_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","article-title":"Voxelotor: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/jpet.121.000743_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/ehm.10.22","article-title":"Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities","volume":"3","author":"Brandow","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1124\/jpet.121.000743_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1537-2995.1980.20681057159.x","article-title":"Viability and function of stored sickle erythrocytes","volume":"20","author":"Castro","year":"1980","journal-title":"Transfusion"},{"key":"10.1124\/jpet.121.000743_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1172\/JCI106294","article-title":"Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia","volume":"49","author":"Charache","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000743_bib11","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V128.22.2452.2452","article-title":"Characterization of metabolic response to AG-348, an allosteric activator of red cell pyruvate kinase, in healthy volunteers and pyruvate kinase deficiency patients","volume":"128","author":"Chubukov","year":"2016","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1172\/JCI109650","article-title":"Deformability of oxygenated irreversibly sickled cells","volume":"65","author":"Clark","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000743_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228399","article-title":"Sickle cell disease: a distinction of two most frequent genotypes (HbSS and HbSC)","volume":"15","author":"da Guarda","year":"2020","journal-title":"PLoS One"},{"key":"10.1124\/jpet.121.000743_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.121.000743_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.V98.3.860","article-title":"Characterization of the phosphatidylserine-exposing subpopulation of sickle cells","volume":"98","author":"de Jong","year":"2001","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib16","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib17","unstructured":"Ericsson A, Green N, Gustafson G, Lancia DR, Jr, Marshall G, Mitchell L, Richard D, Wang Z (2020) inventors, FORMA Therapeutics, Inc., assignee. Activating pyruvate kinase R. U.S. patent 10,675,274. 2020 Jun 9."},{"key":"10.1124\/jpet.121.000743_bib18","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2017-04-590810","article-title":"Disorders of erythrocyte hydration","volume":"130","author":"Gallagher","year":"2017","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bjh.15758","article-title":"How we manage patients with pyruvate kinase deficiency","volume":"184","author":"Grace","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1124\/jpet.121.000743_bib20","first-page":"426","article-title":"Performance characteristics of Hemox-Analyzer for assessment of the hemoglobin dissociation curve","volume":"80","author":"Guarnone","year":"1995","journal-title":"Haematologica"},{"key":"10.1124\/jpet.121.000743_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajh.24975","article-title":"Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks","volume":"93","author":"Hebbel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1124\/jpet.121.000743_bib22","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/jpet.121.000743_bib23","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V126.23.3336.3336","article-title":"Population pharmacokinetics and pharmacodynamics of AG-348 in healthy human volunteers guide dose selection for the treatment of pyruvate kinase deficiency","volume":"126","author":"Kha","year":"2015","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ijlh.12223","article-title":"Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis","volume":"36","author":"Koralkova","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1124\/jpet.121.000743_bib25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","article-title":"AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency","volume":"130","author":"Kung","year":"2017","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.21807","article-title":"The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database","volume":"85","author":"Lanzkron","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1124\/jpet.121.000743_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.tpj.6500433","article-title":"Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea","volume":"7","author":"Ma","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/jpet.121.000743_bib28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2044.1977.tb10002.x","article-title":"Red cell 2,3-diphosphoglycerate and oxygen affinity","volume":"32","author":"MacDonald","year":"1977","journal-title":"Anaesthesia"},{"key":"10.1124\/jpet.121.000743_bib29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fphys.2019.01417","article-title":"Red blood cell deformability, vasoactive mediators, and adhesion","volume":"10","author":"McMahon","year":"2019","journal-title":"Front Physiol"},{"key":"10.1124\/jpet.121.000743_bib30","series-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1124\/jpet.121.000743_bib31","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2015.12.016","article-title":"Crises in sickle cell disease","volume":"149","author":"Novelli","year":"2016","journal-title":"Chest"},{"key":"10.1124\/jpet.121.000743_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1113\/jphysiol.1990.sp018168","article-title":"Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells","volume":"427","author":"Ortiz","year":"1990","journal-title":"J Physiol"},{"key":"10.1124\/jpet.121.000743_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1246-7820(96)80001-2","article-title":"Assessment of qualitative functional parameters of stored red blood cells from donors with sickle cell trait (AS) or with heterozygote (AC) status","volume":"3","author":"Ould Amar","year":"1996","journal-title":"Transfus Clin Biol"},{"key":"10.1124\/jpet.121.000743_bib34","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V85.11.3289.bloodjournal85113289","article-title":"Antisickling effects of 2,3-diphosphoglycerate depletion","volume":"85","author":"Poillon","year":"1995","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.25443","article-title":"Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients","volume":"94","author":"Rab","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1124\/jpet.121.000743_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1432-1327.1999.00506.x","article-title":"Refinement and evaluation of a model of Mg2+ buffering in human red cells","volume":"263","author":"Raftos","year":"1999","journal-title":"Eur J Biochem"},{"key":"10.1124\/jpet.121.000743_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2003-11-3755","article-title":"Abnormal regulation of Mg2+ transport via Na\/Mg exchanger in sickle erythrocytes","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.636609","article-title":"Automated oxygen gradient ektacytometry: a novel biomarker in sickle cell anemia","volume":"12","author":"Sadaf","year":"2021","journal-title":"Front Physiol"},{"key":"10.1124\/jpet.121.000743_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","article-title":"Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study","volume":"17","author":"Shah","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1124\/jpet.121.000743_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00676.x","article-title":"Characteristics of indirect pharmacodynamic models and applications to clinical drug responses","volume":"45","author":"Sharma","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.121.000743_bib41","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/bloodadvances.2020003604","article-title":"FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice","volume":"5","author":"Shrestha","year":"2021","journal-title":"Blood Adv"},{"key":"10.1124\/jpet.121.000743_bib42","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2141.2006.06051.x","article-title":"Identification of an erythroid ATP-dependent aminophospholipid transporter","volume":"133","author":"Soupene","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1124\/jpet.121.000743_bib43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V89.3.1078","article-title":"Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea","volume":"89","author":"Steinberg","year":"1997","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000743_bib44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1100\/tsw.2008.157","article-title":"Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches","volume":"8","author":"Steinberg","year":"2008","journal-title":"ScientificWorldJournal"},{"key":"10.1124\/jpet.121.000743_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1124\/jpet.121.000743_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/asheducation-2007.1.84","article-title":"Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease","volume":"2007","author":"Telen","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1124\/jpet.121.000743_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000743_bib48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1172\/JCI106038","article-title":"Metabolic dependence of red cell deformability","volume":"48","author":"Weed","year":"1969","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000743_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ceca.2011.10.005","article-title":"Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients","volume":"51","author":"Weiss","year":"2012","journal-title":"Cell Calcium"},{"key":"10.1124\/jpet.121.000743_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.604","article-title":"Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers","volume":"8","author":"Yang","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 4","key":"10.1124\/jpet.121.000743_bib51","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/j.amepre.2010.01.001","article-title":"Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007","volume":"38","author":"Yusuf","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1124\/jpet.121.000743_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2005.05527.x","article-title":"Red cell pyruvate kinase deficiency: molecular and clinical aspects","volume":"130","author":"Zanella","year":"2005","journal-title":"Br J Haematol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:26:00Z","timestamp":1739971560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0022356524002441"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000743","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s)","name":"copyright","label":"Copyright"}]}}